1 | Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments. 2025;14: doi: 10.3389/fonc.2024.1514120 |
2 | Long noncoding RNAs as therapeutic targets to overcome chemoresistance in ovarian cancer. 2022;10: doi: 10.3389/fcell.2022.999174 |
3 | Combined radiomics-clinical model to predict platinum-sensitivity in advanced high-grade serous ovarian carcinoma using multimodal MRI. 2024;14: doi: 10.3389/fonc.2024.1341228 |
4 | Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?. 2023;16: doi: 10.1186/s13048-023-01259-2 |
5 | The first-in-class pro-apoptotic peptide PEP-010 is effective in monotherapy and in combination with paclitaxel on resistant ovarian adenocarcinoma cell models. 2024;15: doi: 10.3389/fphar.2024.1444973 |
6 | Ovarian tumor microenvironment contributes to tumor progression and chemoresistance. 2024; doi: 10.20517/cdr.2024.111 |
7 | Production of novel peptide‐targeting antibodies for anti‐Müllerian hormone receptor 2 and induction of cytotoxicity in ovarian cancer cells. 2025;101: doi: 10.1111/sji.13426 |
8 | Immunological modifications following chemotherapy are associated with delayed recurrence of ovarian cancer. 2023;14: doi: 10.3389/fimmu.2023.1204148 |
9 | Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen. 2025;91:220 doi: 10.1111/bcp.16250 |
10 | Nafamostat mesylate sensitizes ovarian cancer cells to carboplatin by promoting the ZNF24-mediated inhibition of WNT2B. 2024;49:467 doi: 10.2131/jts.49.467 |
11 | |
12 | Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models. 2024;42:644 doi: 10.1007/s10637-024-01479-3 |
13 | Exosomal miR-4516 derived from ovarian cancer stem cells enhanced cisplatin tolerance in ovarian cancer by inhibiting GAS7. 2024;927:148738 doi: 10.1016/j.gene.2024.148738 |
14 | Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma. 2023;13: doi: 10.3389/fonc.2023.1252700 |
15 | Multiaction Pt(IV) Complexes: Cytotoxicity in Ovarian Cancer Cell Lines and Mechanistic Studies. 2024;63:14958 doi: 10.1021/acs.inorgchem.4c01586 |
16 | Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor‐α positive ovarian cancer: The antibody–drug conjugate, payload and metabolite. 2024;90:568 doi: 10.1111/bcp.15937 |
17 | |
18 | |
19 | Investigating the role of exosomal long non-coding RNAs in drug resistance within female reproductive system cancers. 2025;13: doi: 10.3389/fcell.2025.1485422 |
20 | Emerging role of m6A modification in ovarian cancer: progression, drug resistance, and therapeutic prospects. 2024;14: doi: 10.3389/fonc.2024.1366223 |
21 | |
22 | Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors. 2024; doi: 10.20517/cdr.2023.152 |
23 | Circular RNAs in gynecologic cancers: mechanisms and implications for chemotherapy resistance. 2023;14: doi: 10.3389/fphar.2023.1194719 |
24 | The role of macrophage polarization in ovarian cancer: from molecular mechanism to therapeutic potentials. 2025;16: doi: 10.3389/fimmu.2025.1543096 |
25 | |
26 | Selected phenotypic and functional changes in ovarian cancer cells treated in vitro with combined therapy using cisplatin and hyperthermia. 2023;77:115 doi: 10.18794/aams/159291 |
27 | Multicompartmentalized Microvascularized Tumor-on-a-Chip to Study Tumor-Stroma Interactions and Drug Resistance in Ovarian Cancer. 2024;17:345 doi: 10.1007/s12195-024-00817-y |